Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBarr (A.G.) Regulatory News (BAG)

Share Price Information for Barr (A.G.) (BAG)

Share Price is delayed by 15 minutes
Get Live Data
613.00    6.00 (0.99%)
Bid:
610.00
Ask:
612.00
Spread: 2.00 (0.328%)
Market Cap: £680.28m
BAG Live PriceLast checked at - London Stock Exchange

Intraday Barr (A.G.) Share Chart

Full Year Trading Update

3 Feb 2026 07:00

RNS Number : 4034R
Barr(A.G.) PLC
03 February 2026
 

IMMEDIATE RELEASE 3 February 2026

A.G. BARR plc

("A.G. BARR" or "the Company")

 

Full Year Trading Update

 

Full year performance in-line with expectations - Double-digit profit growth

 

Acquisitions of Fentimans Ltd and Frobishers Juices Ltd

 

Entering 2026 with good momentum

 

A.G. BARR, the multi-beverage business with a broad portfolio of market-leading UK brands including IRN-BRU, Rubicon and Boost, is pleased to announce a Trading Update in respect of the financial year ended 31 January 2026 ('FY25/26') ahead of announcing Final Results on 31 March 2026.

 

FY25/26 Highlights

The Company delivered a strong performance in FY25/26 in-line with expectations.

During the year the Company outlined its key strategic drivers, including brand innovation pipeline development, channel expansion initiatives and investment in operational capabilities. Good progress has been made in these areas and FY26/27 is expected to be a year of building momentum. 

The Company is also delighted to announce the acquisitions of Fentimans Ltd ('Fentimans'), the soft drinks and mixers brand known for its "Botanical Brewing" process, and Frobishers Juices Ltd ('Frobishers'), the premium natural fruit juices and soft drinks brand. Both brands operate in the attractive Adult Soft Drinks market, which is benefitting from the consumer trend of reduced alcohol consumption. These acquisitions reflect the execution of further meaningful and targeted M&A to elevate growth through broadening the brand portfolio while providing opportunities for cost synergies.

Financials

Revenue growth of c.4% to c.£437m (FY24/25: £420m).

● Adjusted Operating Margin of c.14.7% (FY24/25: 13.6%), an increase of c.110 bps, contributing to double-digit profit1 growth. This is driven by benefits from on-going efficiency initiatives and supply chain investment.

● Adjusted Return on Capital Employed maintained at target level of c.20%.

Operational and Strategic

● Marketing and distribution initiatives supporting IRN-BRU deliver modest growth in H2 following a flat H1, with good performances from Rubicon and Boost offsetting a decline in FUNKIN.

● Innovation activity significantly expanded, with a series of new product launches taking place from January 2026.

● Continued investments in manufacturing sites improving both capacity and capability, delivered as planned and on budget.

● Acquisition of Frobishers for £13m, completed towards the period end, funded from the Company's net cash position.

Post Period-End

● Acquisition of Fentimans completed on 2 February 2026 for c.£38m, funded through a combination of cash and debt.

● Integration of both Fentimans and Frobishers to take place during FY26/27, with associated efficiencies beginning to come through from H2.

● Strong brand activity pipeline continuing through FY26/27, including redesigns of IRN-BRU and Rubicon and further innovation launches.

Euan Sutherland, Chief Executive Officer, commented:

"We are pleased to report a strong year that highlights delivery of our strategic priorities. Our top and bottom line performance for FY25/26 is in line with expectations, and importantly we have laid strong foundations for future growth. We enter FY26/27 with good momentum in our core brands and from the introduction of exciting new products. In-line with our strategy of enhancing our organic growth with M&A, we are delighted to announce the acquisitions of Fentimans and Frobishers. The synergies associated with these acquisitions are expected to drive meaningful accretion over the medium term. Underpinning all our activity is our consistent focus on efficiency, margin and growing shareholder returns."

For more information:

A.G. BARR MHP GROUP

 

0330 390 3900 07801 894 577

ir@agbarr.co.uk agbarr@mhpgroup.com

Euan Sutherland, Chief Executive Officer Oliver Hughes

Stuart Lorimer, Chief Finance and Operating Officer Rachel Farrington

Ewan Dytch, Corporate Finance Director Veronica Farah

 

1 - Adjusted profit before tax

Year-on-year metrics reflect the full year 2025/26 53 weeks compared against 2024/25.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTEAPAAEFAKEFA
Date   Source Headline
3rd Jun 20267:00 amRNS-RLaunch of IRN-BRU Summer Campaign
27th May 20263:00 pmRNSDirector/PDMR Shareholding
26th May 20261:30 pmRNSDirector/PDMR Shareholding
22nd May 20262:00 pmRNSResult of AGM
11th May 20262:46 pmRNSDirector/PDMR Shareholding
21st Apr 202610:43 amRNSAnnual Report and Accounts and Notice of AGM
16th Apr 20267:00 amRNSDirector/PDMR Shareholding
14th Apr 20267:00 amRNSDirector/PDMR Shareholding
13th Apr 20269:39 amRNSDirector/PDMR Shareholding
7th Apr 202611:21 amRNSDirector/PDMR Shareholding
1st Apr 20268:44 amRNSDirector/PDMR Shareholding
31st Mar 20267:00 amRNSFinal Results
23rd Mar 20267:00 amRNS-RLaunch of IRN-BRU 'ZERO'
10th Mar 20267:00 amRNSDirector/PDMR Shareholding
3rd Mar 20267:00 amRNSNotice of Results Presentation
9th Feb 20263:56 pmRNSDirector/PDMR Shareholding
4th Feb 20264:16 pmRNSHolding(s) in Company
3rd Feb 20267:00 amRNSFull Year Trading Update
15th Jan 20267:00 amRNSDirectorate change
12th Jan 202611:00 amRNSDirector/PDMR Shareholding
8th Dec 20252:49 pmRNSDirector/PDMR Shareholding
19th Nov 20251:44 pmRNSHolding(s) in Company
17th Nov 20253:25 pmRNSDirector/PDMR Shareholding
10th Nov 20254:44 pmRNSDirector/PDMR Shareholding
10th Nov 20254:38 pmRNSDirector/PDMR Shareholding
8th Oct 20252:39 pmRNSDirector/PDMR Shareholding
30th Sep 20257:00 amRNSInterim Results
11th Sep 20252:00 pmRNSNotice of Results
10th Sep 20256:00 pmRNSDirector/PDMR Shareholding
28th Aug 20252:00 pmRNS2025 Annual General Meeting Update
12th Aug 20254:01 pmRNSDirector/PDMR Shareholding
1st Aug 20257:01 amRNSDirector Declaration
29th Jul 20257:00 amRNSTrading Statement
9th Jul 202511:00 amRNSAppointment of Non-Executive Director
8th Jul 20252:02 pmRNSDirector/PDMR Shareholding
3rd Jul 202511:09 amRNSDirector/PDMR Shareholding
11th Jun 202511:01 amRNSDirector/PDMR Shareholding
10th Jun 20254:20 pmRNSDirector/PDMR Shareholding
10th Jun 20252:02 pmRNSDirector/PDMR Shareholding
3rd Jun 20257:00 amRNSCapital Markets Event
23rd May 20255:36 pmRNSResult of AGM
12th May 20251:54 pmRNSDirector/PDMR Shareholding
30th Apr 20259:15 amRNSPotential disposal of Strathmore Business
28th Apr 20253:16 pmRNSDirector/PDMR Shareholding
28th Apr 20253:15 pmRNSDirector/PDMR Shareholding
22nd Apr 202510:24 amRNSAnnual Financial Report
9th Apr 202511:23 amRNSDirector/PDMR Shareholding
8th Apr 20253:29 pmRNSDirector/PDMR Shareholding
25th Mar 20257:00 amRNSResults for year ended 25 January 2025
10th Mar 20252:04 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.